Natalizumab effects on immune cell responses in multiple sclerosis

Annals of Neurology
Masaaki NiinoAmit Bar-Or

Abstract

Our objective was to study in vivo biological effects of natalizumab on immune cell phenotype and function in multiple sclerosis (MS) patients. Blood was obtained before and after serial monthly natalizumab infusions to track functional expression of VLA-4 and migratory capacity of immune cells. The impact of infusion on activation thresholds of immune cells was evaluated. Preinfusion VLA-4 expression differed across immune cell subsets. Natalizumab significantly, albeit partially, diminished VLA-4 expression on circulating immune cells. Cell subsets were differentially affected. Treatment significantly decreased migratory capacity of immune cells, correlating well with changes in VLA-4 expression. Effects of a single dose were not saturating and did not persist through the monthly dose interval. Infusion effect varied across patients but was remarkably stable in individual patients, over multiple infusions. Treatment significantly modulated proliferative responses of immune cells. To our knowledge, we provide first proof of concept that natalizumab diminishes migratory capacity of immune cells. Our prospective study further shows that effects of therapy likely (1) differ for distinct immune cell subsets, (2) are not sustained ...Continue Reading

References

Mar 1, 1983·Annals of Neurology·C M PoserW W Tourtellotte
Dec 20, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·P W DudaD A Hafler
Dec 26, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·Igor J KoralnikNorman L Letvin
Mar 14, 2002·Archives of Neurology·Alexandre PratJack P Antel
Jan 3, 2003·The New England Journal of Medicine·David H MillerUNKNOWN International Natalizumab Multiple Sclerosis Trial Group
Apr 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrea AlterAmit Bar-Or
May 2, 2003·Journal of Neuropathology and Experimental Neurology·Rosanne SéguinJack P Antel
Jun 11, 2005·The New England Journal of Medicine·Annette Langer-GouldDaniel Pelletier
Jun 11, 2005·The New England Journal of Medicine·B K Kleinschmidt-DeMasters, Kenneth L Tyler

❮ Previous
Next ❯

Citations

Jul 14, 2010·Archives of Neurology·Olaf StüveTodd N Eagar
May 17, 2008·Zeitschrift für Rheumatologie·C Kneitz, H Wiendl
Nov 16, 2007·Journal of Neurology·Christoph KleinschnitzHeinz Wiendl
May 10, 2007·Current Neurology and Neuroscience Reports·Eric C Klawiter, Anne H Cross
Oct 9, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Paolo A Muraro, Bibiana Bielekova
Nov 24, 2006·The Neurologist·Allen J Aksamit
Feb 18, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M KhademiT Olsson
Mar 1, 2009·Therapeutic Advances in Neurological Disorders·Ozgür Yaldizli, Norman Putzki
Oct 7, 2008·PloS One·Max-Philipp StennerHeinz Wiendl
Dec 12, 2012·PloS One·Lars BörnsenFinn Sellebjerg
Mar 25, 2008·Therapeutics and Clinical Risk Management·Michael Hutchinson
Aug 27, 2009·Therapeutics and Clinical Risk Management·Brandon A Brown
Aug 12, 2014·Gastroenterology Clinics of North America·Sara Horst, Sunanda Kane
Dec 4, 2013·Journal of Neurovirology·Sarah Beltrami, Jennifer Gordon
Oct 6, 2015·Immunological Investigations·Nourollah RamroodiMohammad Abdollahi
Mar 19, 2008·Expert Review of Neurotherapeutics·Mathias Buttmann, Peter Rieckmann
Mar 26, 2013·Expert Opinion on Biological Therapy·Luisa Klotz, Heinz Wiendl
Sep 4, 2008·Expert Opinion on Emerging Drugs·Claudio GasperiniCarlo Pozzilli
Jan 19, 2016·Frontiers in Immunology·Rui LiUNKNOWN MSSRF Canadian B cells in MS Team
Aug 16, 2012·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Cinzia ZanottiLuisa Imberti
Jun 27, 2012·Neuroscience Letters·Masaaki NiinoSeiji Kikuchi
Jul 29, 2008·Neurologic Clinics·Thomas Weber
May 10, 2011·Journal of Neuroimmunology·Mario SkaricaPeter A Calabresi
Mar 29, 2011·Neurologic Clinics·James J Marriott, Paul W O'Connor
Oct 26, 2010·Journal of Neuroimmunology·Antje Vogelgesang, Alexander Dressel
Mar 24, 2016·Neurology. Neuroimmunology and Neuroinflammation·Kimitoshi KimuraTakashi Yamamura
Oct 6, 2009·Progress in Neurobiology·Nathalie KoningRobert M Hoek
Aug 12, 2009·Neuroscience Letters·Masaaki NiinoHidenao Sasaki
Jan 28, 2009·Prostaglandins, Leukotrienes, and Essential Fatty Acids·L ShintoD Bourdette
Nov 15, 2007·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Raoul D Oude EngberinkHelga E de Vries
Nov 13, 2008·Matrix Biology : Journal of the International Society for Matrix Biology·Koyu ItoToshimitsu Uede
Aug 16, 2008·Lancet Neurology·Diego FranciottaFrancesca Aloisi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.